NEW YORK, September 15, 2014—Kantar Health, a leading global healthcare consulting firm, has acquired Evidências, an industry leader in evidence-based, health management services in Brazil. Known for its strong scientific reputation, Evidências works with all segments of the Brazilian healthcare market, including health insurers, government bodies, hospitals and providers, and pharmaceutical and medical device manufacturers.
The acquisition expands Kantar Health’s presence in an important emerging market and provides the company with new capabilities in cost effectiveness and budget impact economic models, local dossier submission packages and professional writing. Kantar Health also receives valuable expertise in the DATASUS governmental database and a key private insurance database covering 20 percent of the privately insured population in Brazil – offering a complete picture of the healthcare sector in the country. Evidências gains access to Kantar Health’s leading data assets and global team of healthcare consultants, allowing Evidências to strengthen its work in evidence-based medicine and further extend its range of services in consulting, market access and training.
“This partnership brings together two highly talented and scientific teams and further strengthens Kantar Health’s presence in this important emerging healthcare market,” said Mike Kelly, CEO Americas, Kantar Health. “Combined, Kantar Health and Evidências will give clients unparalleled access to new sources of healthcare information and enhanced scientific expertise, health economics modeling, clinical studies and market access.”
Through this acquisition, Kantar Health will be able to provide better coordination of market access and health outcomes in Brazil, while allowing both companies to expand their current client bases and deliver local support for Kantar Health’s National Health and Wellness Survey, CancerMPact®, Forecast Architect® and Epi Database® offers.
“Evidências has established itself as one of the premier health management companies in Brazil through our focused approach to evidence-based medicine and enhanced decision making for health technologies and market analysis,” said Otávio Clark, President and Projects Development Team Leader for Evidências. “We are excited to become part of Kantar Health and look forward to continuing to deliver unprecedented scientific, health outcomes and market access expertise to clients in Brazil.”
About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.
Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 600+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. Kantar Health is part of Kantar, the data investment management division of WPP. For more information, please visit www.kantarhealth.com.
Evidências was established in 1998 with the objective of solving problems through the techniques of Evidence Based Medicine (EBM) and assist in decision-making related to health technologies and market analysis. In its 15 years, the company has established itself as one of main companies in the area of health management in the country. It offers various services, such as courses and training, analysis of cases of high complexity in health, technical support to the legal advice of health technologies, construction of protocols and clinical guidelines, medical bills in oncology audit, dossiers for drug registration and incorporation of health technologies, consulting for specialty societies, economic studies and pharmacoeconomics projects. For more information, please visit www.evidencias.com.br.